fbpx

News

Lundbeckfonden Ventures News

Today only an average of 50% of stroke survivors recovers full use of their arm. A study from the Rehabilitation Institute of Chicago approached stroke rehabilitation through a new combination of therapies which produced significantly greater gains in their motor function 6 months post stroke. The series of combination therapy used non-invasive navigated transcranial stimulation...
SAN DIEGO, CA, January 29, 2014 – Celladon Corporation (NASDAQ: CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today the pricing of its initial public offering of 5,500,000 shares of its common stock at $8.00 per share. Celladon has also granted...
Edinburgh – 7 January 2014 ? DySIS Medical Ltd, a medical devices company active within Women’s Health, today announces that Robert Cascella has joined as Chairman of the board of directors of the Company effective January 2014. His appointment further strengthens the board following a year of investment and growth in 2013. Mr. Cascella was...
BAGNEUX, France, Dec. 17, 2013 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today a summary of corporate activities in 2013 and provided news flow guidance for 2014. Dr. Pierre-Henri Benhamou, Chairman & CEO of DBV Technologies, said: It has been an extremely...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today the presentation of Epicutaneous Immunotherapy for Food Allergy” at a meeting of the World Allergy Organization by Dr. Hugh Sampson, Kurt Hisrchhorn Professor of Pediatrics, Director of the Jaffe Food Allergy Institute and Dean of...
Ongoing CUPID 2 Study Potential to Serve as Primary Basis of Efficacy and Safety Required for MMA Submission in European Union Celladon Corporation, a clinicalstage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that the Company has received requested scientific advice from the...
. Agreement established after positive pre-clinical results were obtained by DBV and University of Geneva combining DBV’s and BioNet’s unique technologies . A Phase I, clinical proof of concept study will be initiated in H2 2014 by the University of Geneva DBV Technologies (Euronext Paris: DBV), creator of Viaskin®, announced today that it has entered...
–Continued reduction in cardiovascular events and no safety concerns observed through three years of follow up in the MYDICAR high dose group-–Oral Presentation by Dr. Barry H. Greenberg at 9 AM CET on November 19, 2013 — Celladon Corporation, a clinicalstage biotechnology company focused on developing novel therapies by applying its leadershipposition in the field...
First-in-Class Anabolic Catabolic Transforming Agent Shown to Reverse Cachexia's Effects in Stage III and IV Lung and Colorectal Cancer Patients PsiOxus Therapeutics, Ltd. (PsiOxus) today announced top line positive data from a Phase II clinical trial of MT-102 in cancer-related cachexia. The primary endpoint has been met in the recently completed Phase II multinational, randomized,...
1 44 45 46 47 48 58

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Acacia Pharma Group plc – Issue of Equity on Exercise of Options
16. August 2019
Acacia Pharma Group PLC – Acacia Pharma Group plc: Notice of Interim Results
12. August 2019
Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)
31. July 2019